Cambridge Associates’s Amicus Therapeutics FOLD Stock Holding History

Cambridge Associates’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-29,348	Closed	-$280K	–	46
2021 Q3	$280K	Buy	+29,348	New	+$300K	0.02%	46

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cambridge Associates's FOLD Position: Q4 2021 in Review

Cambridge Associates sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 29,348 shares — an estimated $280K sold.

Cambridge Associates first reported a position in FOLD in Q3 2021 and held it in 1 quarter. The position peaked at $280K in Q3 2021. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

Cambridge Associates reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
Cambridge Associates sold 29,348 Amicus Therapeutics shares in Q4 2021, an estimated $280K.
Cambridge Associates first reported a position in Amicus Therapeutics in Q3 2021 and held it in 1 quarter.
Cambridge Associates's Amicus Therapeutics position peaked at $280K in Q3 2021.
224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Cambridge Associates's 13F filing for Q4 2021, filed 11 Feb 2022.